Is the dose of Larotrectinib the same for children and adults?

Larotrectinib is a highly selective TRK inhibitor, mainly used to treat patients with solid tumors with NTRK gene fusions. This drug is suitable for patients of different age groups, including children and adults. However, due to differences in age, physiological state, and metabolic capacity, the dosage settings for children and adults are not exactly the same when using larotrectinib.

First, adult patients typically take larotrectinib at a fixed dose. According to the recommended protocol, the standard dose for adults and adolescent patients weighing more than 18 kg is 100 mg orally twice daily. This dose has been verified in multiple clinical trials, which not only ensures the efficacy of the drug, but also controls the frequency of side effects within a safe range. This dose is suitable for most adult patients with solid tumors, including non-small cell lung cancer, thyroid cancer, soft tissue sarcoma, etc.

In contrast, dosage in pediatric patients is often individualized based on body weight. For children weighing less than 18 kg, the recommended dose is 1 mg/kg twice daily. This allows for more precise control of drug concentrations and avoids toxic reactions caused by overdose. Larotrectinib is also widely used in pediatric tumors, including rare NTRK fusion tumors in infants and young children, such as infantile fibrosarcoma, congenital central nervous system tumors, etc.

It is important to emphasize that both adults and children require close monitoring during the use of larotrectinib, including liver function tests, electrocardiograms, and imaging evaluations. In addition, if the patient experiences obvious adverse drug reactions, such as fatigue, elevated transaminases, nervous system abnormalities, etc., the doctor may adjust the dose or suspend the medication according to the situation. Therefore, although larotrectinib has shown good efficacy and tolerability in patients of all ages, its dosage still needs to be accurately set based on individual circumstances to ensure maximum efficacy while reducing potential risks.

Reference materials:https://www.vitrakvi.com/